Insulin resistance is a pathophysiological state in which target tissues (primarily skeletal muscle, liver, and adipose) respond inadequately to insulin. Clinically, it often presents with compensatory hyperinsulinemia, impaired glucose tolerance, and progression toward type 2 diabetes. Beyond glycemic effects, insulin resistance is increasingly recognized as a central driver of the cardiometabolic abnormalities that culminate in atherosclerotic cardiovascular disease. The seed concept relates to the idea that heart disease processes begin upstream with metabolic dysfunction rather than being solely attributable to cholesterol in isolation.
At the cellular level, insulin resistance arises from impaired insulin signaling. Key mechanisms include serine/threonine phosphorylation of insulin receptor substrates, altered downstream phosphatidylinositol signaling, mitochondrial dysfunction, and chronic low-grade inflammation. Excess energy availability—commonly from diets high in added sugars and refined carbohydrates—promotes ectopic fat deposition in liver and muscle (hepatic steatosis and myosteatosis), which disrupts normal insulin action. Adipose tissue dysfunction also contributes: adipocytes become pro-inflammatory and lipolysis increases, elevating free fatty acids that further impair insulin signaling.
A typical downstream consequence is hepatic overproduction of glucose, due to increased gluconeogenesis and reduced suppression by insulin. In parallel, the liver’s lipid handling becomes abnormal. Insulin normally restrains lipolysis and modulates hepatic very-low-density lipoprotein (VLDL) secretion and apolipoprotein metabolism; when insulin signaling is defective, dyslipidemia patterns emerge. Atherogenic dyslipidemia often includes elevated triglycerides, low high-density lipoprotein (HDL) cholesterol, and the presence of small dense low-density lipoprotein (LDL) particles. Small dense LDL has greater arterial wall penetration and susceptibility to oxidative modification, supporting plaque development.
Insulin resistance also promotes a pro-atherogenic vascular environment. Hyperinsulinemia and associated metabolic stress can increase oxidative stress and reduce endothelial nitric oxide bioavailability, impairing vasodilation and favoring leukocyte adhesion. Endothelial dysfunction is a key early step in atherosclerosis. The metabolic milieu further enhances inflammatory signaling pathways (including cytokine release and activation of innate immune responses within vessel walls). Smooth muscle cell proliferation and migration, along with extracellular matrix remodeling, contribute to plaque growth and instability.
Hyperglycemia and glycation end-products, particularly as insulin resistance advances toward diabetes, add additional arterial injury. Advanced glycation end-products can crosslink proteins and modify lipoproteins, increasing oxidative stress and inflammatory signaling. Even before overt diabetes, postprandial glucose excursions associated with insulin resistance can induce endothelial dysfunction and oxidative damage.
The clinical implication is that cardiovascular risk reduction should address the upstream metabolic drivers. Lifestyle interventions are foundational. Dietary patterns emphasizing whole foods, high fiber content, adequate protein, and restriction of added sugars and refined starches can improve insulin sensitivity by reducing ectopic fat and lowering inflammatory signaling. Weight loss, even modest amounts, can significantly enhance insulin action and reduce triglycerides. Physical activity improves insulin-mediated glucose uptake through increased GLUT4 translocation and enhanced mitochondrial function, thereby reducing insulin resistance.
Pharmacologic approaches may also target insulin resistance and its downstream consequences. For example, metformin improves hepatic insulin sensitivity and reduces gluconeogenesis. In higher-risk patients with type 2 diabetes or established cardiovascular disease, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated cardiovascular benefits that extend beyond glucose lowering, likely via weight reduction, improved endothelial function, and favorable metabolic and hemodynamic effects.
It is important to contextualize cholesterol in modern cardiometabolic theory. Cholesterol—particularly LDL cholesterol—is strongly associated with atherosclerotic plaque burden and is a causal factor in many pathways of atherosclerosis. However, insulin resistance can determine the lipid phenotype, particle characteristics, and inflammatory/oxidative state that govern plaque formation and progression. Therefore, focusing solely on cholesterol without addressing insulin resistance can miss upstream drivers that sustain an atherogenic environment.
In summary, insulin resistance is not merely a precursor to diabetes; it is a systemic metabolic disorder that actively orchestrates vascular dysfunction, dyslipidemia, inflammation, and oxidative stress. These changes create conditions conducive to atherosclerosis and heart disease, aligning with the concept that the process begins with impaired insulin action and years of metabolic strain. Source: @amerix
Eric: The system has brainwashed people to believe that CHOLESTEROL is the cause of heart disease. IT IS NOT. The process of heart disease begins with INSULIN RESISTANCE. Insulin resistance is a condition caused by years of eating sugar and refined carbs. When cells become. #breaking
— @amerix May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
